CALIDI BIOTHERAPEUTICS, INC.
Ownership & governance
Executives 5Directors 6Avg age 61Avg tenure 3y
EP
Eric Poma
Chief Executive Officer
Age 54Since 2025-04-21Profile →
+10
Executives5
EP
Eric Poma→
Chief Executive Officer
Age 54Since 2025-04-21
AJ
Andrew Jackson
Director of Finance/CFO
Age 57Since 2023-10-29
GC
Guy Clifton
Chief Tech/Sci/R&D Officer
—Since 2025-04-09
AS
Antonio Santidrian
Chief Tech/Sci/R&D Officer
Age 47—
AC
Allan Camaisa
Chief Executive Officer
Age 66Since 2015-07-31
Board of directors6
SL
Scott Leftwich→
Director/Board Member
Age 65Since 2019-04-30
JS
James Schoeneck→
Chairman
Age 68Since 2025-03-31
AS
Alan Stewart→
Director/Board Member
Age 62Since 2023-10-09
GP
George Peoples→
Director/Board Member
Age 64Since 2024-06-30
EP
Eric Poma→
Director/Board Member
Age 54Since 2025-04-21
CS
Corazon Sanders→
Director/Board Member
Age 69Since 2026-06-16
Shareholders5
| Name | Stake | Shares |
|---|---|---|
| Armistice Capital LLC | 24.58 % | 879,000 |
| Sabby Management LLC | 12.16 % | 434,903 |
| Warberg Asset Management LLC | 6.99 % | 250,000 |
| Scott Leftwich | 4.1 % | 146,631 |
| James Schoeneck | 2.363 % | 84,514 |
Catalog · 2026-07-09
Registry officers8
| Name | Role | Since | Shares |
|---|---|---|---|
| James Schoeneck | Chairman | 2025-03-31 | - |
| Alan Stewart | Director/Board Member | 2023-10-09 | - |
| Chief Executive Officer and Director | Director or executive officer | — | 66,394 |
| Chief Financial Officer | Director or executive officer | — | 6,614 |
| Corazon Sanders | Director/Board Member | 2026-06-16 | - |
| Eric Poma | Director/Board Member | 2025-04-21 | - |
| George Peoples | Director/Board Member | 2024-06-30 | - |
| Scott Leftwich | Director/Board Member | 2019-04-30 | - |
Registry · as of 2026-07-09
Institutional (13F)
Loading Form 13F holders…
Fund membership
Loading fund baskets…
Street consensus
Consensus none
Broker actions6
| Firm | Action | To | Target | Date |
|---|---|---|---|---|
| Ladenburg Thalmann | Initiated | Buy | 1 | 2024-06-27 |
| Baird | Maintained | Outperform | 2 | 2024-05-15 |
| Baird | Maintained | Outperform | 4.5 | 2024-03-21 |
| HC Wainwright & Co. | Maintained | Buy | 2 | 2024-03-21 |
| HC Wainwright & Co. | Initiated | Buy | 11 | 2023-11-22 |
| Baird | Initiated | Outperform | 9 | 2023-10-09 |
Firm rows and rating mix from Yahoo Finance; mean target is Yahoo’s aggregate until OpenFilings derives consensus from broker rows.